Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide

Patent No. EP3954690 (titled "Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide") was filed by Acerta Pharma on Jul 1, 2016. The application was issued on Apr 5, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
KRAUS & LEDERER PARTGMBBDec 29, 2023KRAUS & LEDERER PARTGMBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3954690

ACERTA PHARMA
Application Number
EP21182842A
Filing Date
Jul 1, 2016
Status
Revoked
May 16, 2025
Publication Date
Apr 5, 2023